Citius Pharmaceuticals
CTXR
55 hedge funds and large institutions have $16.9M invested in Citius Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 11 closing their positions.
370% more call options, than puts
Call options by funds: $574K | Put options by funds: $122K
50% more capital invested
Capital invested by funds: $11.2M → $16.9M (+$5.65M)
2% more funds holding
Funds holding: 54 → 55 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more ownership
Funds ownership: 0.39% → 0.39% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$259K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$150K |
| 3 |
CCC
Chelsea Counsel Company
Los Angeles,
California
|
+$93.7K |
| 4 |
HGWM
Horst & Graben Wealth Management
Portland,
Oregon
|
+$87.3K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$86.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$352K |
| 2 |
Millennium Management
New York
|
-$284K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$53.3K |
| 4 |
Man Group
London,
United Kingdom
|
-$53.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$48.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APC
51
Aspire Private Capital
Cornelius,
North Carolina
| $351 | – | – | – |
|
|
FWM
52
Focused Wealth Management
Newburgh,
New York
| $316 | – | – | – |
|
|
WWP
53
WR Wealth Planners
Columbia,
Missouri
| $117 | +$115 | +4 | New |
|
54
Commonwealth Equity Services
Waltham,
Massachusetts
| $33 | – | – | – |
|
55
Bank of America
Charlotte,
North Carolina
| $23 | -$144 | -5 | -83% |
|
|
TSS
56
Two Sigma Securities
New York
| – | -$48.7K | -2,465 | Closed |
|
57
Marshall Wace
London,
United Kingdom
| – | -$40.3K | -2,038 | Closed |
|
|
VF
58
Virtu Financial
New York
| – | -$31K | -1,560 | Closed |
|
59
Goldman Sachs
New York
| – | -$10.5K | -534 | Closed |
|
|
SG
60
StoneX Group
New York
| – | -$8.77K | -444 | Closed |
|
61
US Bancorp
Minneapolis,
Minnesota
| – | -$1.58K | -80 | Closed |
|
62
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$316 | -16 | Closed |
|
|
IA
63
IFP Advisors
Tampa,
Florida
| – | -$1K | -8 | Closed |
|
CTXR Hedge Fund Activity: Q1 2023 in Review
55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2023, worth a combined $16.9M — up 50% from $11.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CTXR positions and 11 closed out — a net gain of 1 holder — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Jane Street, adding an estimated $259K. The largest seller was Citadel Advisors, cutting an estimated $352K.
- 55 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2023, up from 54 in Q4 2022.
- Funds reported $16.9M of Citius Pharmaceuticals stock for Q1 2023, up 50% quarter-over-quarter.
- 12 funds opened new Citius Pharmaceuticals positions in Q1 2023 and 11 closed out, a net change of +1 holder.
- The largest Citius Pharmaceuticals buyer in Q1 2023 was Jane Street, an estimated $259K added.
- The largest Citius Pharmaceuticals seller in Q1 2023 was Citadel Advisors, an estimated $352K sold.
Based on aggregated 13F filings for Q1 2023.